Department of Urology, Oslo University Hospital, Oslo, Norway.
Int J Urol. 2011 Sep;18(9):646-51. doi: 10.1111/j.1442-2042.2011.02815.x. Epub 2011 Jul 20.
To evaluate health-related quality of life (HRQOL) after salvage high-intensity focused ultrasound (HIFU) for locally radiorecurrent prostate cancer (PCa).
Since June 2006 we have treated 61 patients consecutively by salvage HIFU. All patients were offered the University of California, Los Angeles Prostate Cancer Index (UCLA-PCI) questionnaire at baseline and at follow-up. Scores ranged from 0 (worst) to 100 (best). Clinically significant changes were defined as a minimum difference of 10 points between the baseline score and the score at follow-up.
Fifty-seven patients (93%) had evaluable data at baseline, compared with 46 (75%) after treatment. The mean time lapse between HIFU treatment and questionnaire response was 17.5 months (range 6-29 months). The mean score for urinary function decreased from 79.7 ± 12.1 prior to HIFU to 67.4 ± 17.8 after HIFU (P < 0.001). The mean score for sexual function decreased from 32.1 ± 24.1 prior to HIFU to 17.2 ± 17.0 after HIFU (P < 0.001). There were no significant effects on bowel function. There was a significant reduction in the mean score for Physical HRQOL, but the mean score for Mental HRQOL was did not change significantly.
Treatment of localized radiorecurrent PCa by salvage HIFU is associated with clinically significant reductions in urinary and sexual function domains after a mean follow-up of 17.5 months.
评估高强度聚焦超声(HIFU)挽救性治疗局部放射性复发性前列腺癌(PCa)后的健康相关生活质量(HRQOL)。
自 2006 年 6 月以来,我们连续对 61 例患者进行了 HIFU 挽救性治疗。所有患者均在基线和随访时接受加利福尼亚大学洛杉矶分校前列腺癌指数(UCLA-PCI)问卷评估。评分范围为 0(最差)至 100(最佳)。临床显著变化定义为基线评分与随访评分之间至少相差 10 分。
57 例患者(93%)在基线时有可评估数据,而治疗后有 46 例(75%)。HIFU 治疗与问卷反应之间的平均时间间隔为 17.5 个月(范围 6-29 个月)。尿功能评分从 HIFU 治疗前的 79.7±12.1 降至 HIFU 治疗后的 67.4±17.8(P<0.001)。性功能评分从 HIFU 治疗前的 32.1±24.1 降至 HIFU 治疗后的 17.2±17.0(P<0.001)。HIFU 对肠功能无显著影响。HIFU 治疗后,生理 HRQOL 评分显著降低,但心理 HRQOL 评分无明显变化。
HIFU 挽救性治疗局部放射性复发性 PCa 与尿功能和性功能领域的临床显著降低相关,平均随访 17.5 个月后。